A Zika vaccine based on chimpanzee adenovirus ChAdOx1 elicits lineage-transcending sterile immunity and prevents colonisation of brain and ovaries
Introduction Introduction Main Material and Methods Contributions Competing interests References Zika virus (ZIKV) continuous spread has affected more than 80 countries1 and no licenced vaccine is currently available2. The Asian-lineage is the causative agent of major outbreaks across the globe and most of the current ZIKV vaccine candidates aim to provide homologous efficacy in ZIKV pre-clinical challenge models2,3. In contrast, the African-lineage of ZIKV is mainly restricted to sylvatic transmission but not much is known about the ability of this virus to emerge from a sylvatic to human transmission. Efficacy of ZIKV vaccine in mice or macaques relies on the quantification of viraemia by RT-PCR ...
pathology↗